Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
11:25am, Tuesday, 02'nd Jun 2026
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib
12:28pm, Monday, 01'st Jun 2026
Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor, under a licensing agreement with South Korea's Oscotec, the company said
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
10:46am, Monday, 01'st Jun 2026
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios' rare hematology portfolio with expansion into immune thrombocytopenia, unlo
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
12:32pm, Friday, 29'th May 2026
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
Agios scraps blood cancer drug program after study miss
07:21am, Friday, 29'th May 2026
Agios Pharmaceuticals said on Friday it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show enough benefit.
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
07:00am, Friday, 29'th May 2026
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) --
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
12:11pm, Monday, 25'th May 2026
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
AMSTERDAM--(BUSINESS WIRE)-- #Avanzanite--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its par
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
09:15am, Friday, 22'nd May 2026
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., S
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
01:04pm, Tuesday, 19'th May 2026
Agios Pharmaceuticals NASDAQ: AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently subm
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
12:25pm, Wednesday, 13'th May 2026
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
09:31am, Tuesday, 12'th May 2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 202
